Anti-Biofilm Wound Dressing Market

Market Overview

The global anti-biofilm wound dressing market size was valued at USD 660 million in 2021 and is estimated to reach an expected value of USD 1.48 billion by 2030 at a CAGR of 9.4% during the forecast period (2022-2030). 

The worldwide increase in chronic diseases, like cancer and diabetes, is fueling market growth. Factors such as unhealthy and sedentary lifestyles, antimicrobial resistance, alcohol consumption, and smoking contribute to the growing prevalence of non-communicable diseases. As per the studies conducted by B. Braun Melsungen AG in 2018, around 2.0% to 10.0% of diabetic people suffer from diabetic foot ulcers. In addition, as per the American College of Physicians, in 2017, the global incidence rate of diabetic foot ulcers was around 6.3%, and the lifetime incidence rate in patients with diabetes ranges from 19.0%-34.0%. Since anti-biofilm wound dressing products are highly recommended for treating chronic wounds, thus this factor is expected to boost the market growth significantly. 

Market Dynamics

Global Anti-Biofilm Wound Dressing Market Drivers

Increasing Prevalence of Chronic Diseases

The likelihood of acquiring chronic wounds rises with the rising frequency of chronic diseases like cancer, diabetes, and Deep Vein Thrombosis (DVT), which is anticipated to fuel market growth. A diabetic foot ulcer is a wound typically seen in around 15% of patients with diabetes. Out of 15% of people with a foot ulcer, about 6% are hospitalized due to infection, driving the need for wound treatment. The National Cancer Institute estimates that in the United States, 1,735,350 new cancer cases were diagnosed in 2018. The demand for anti-biofilm wound dressings may increase as malignant wound treatments become more common due to the rising cancer incidence.

The rising prevalence of DVT increases the likelihood of patients acquiring venous ulcers. The CDC estimates that each year in the U.S., about 900,000 people could be impacted by DVT. Between 20% and 50% of them may experience Post-thrombotic Syndrome (PTS), and between 5% and 10% may experience venous ulcers. Similarly, it is anticipated that rising pressure ulcer prevalence, commonly known as bed sores or pressure sores, will further support market expansion. According to the European Pressure Ulcer Advisory Panel, pressure ulcers may develop in 5% of community nursing patients and 10% of hospital patients at some point.

Additionally, adults 65 years and older are far more likely to get pressure ulcers. Pressure ulcers affect 72% of adults 65 years of age and older. Therefore, the growing prevalence of chronic ulcers is expected to propel the anti-biofilm wound dressing market.

Rising Adoption of Ambulatory Surgery Centers

Ambulatory Surgical Centers (ASCs) are transforming healthcare delivery by providing low-risk procedures in a convenient setting. ASCs offer courses lower than other medical settings, such as hospitals. Growing Medicare spending for improving ASCs is also expected to contribute to market growth. In 2017, Medicare program beneficiaries spent USD 4.6 billion on ASC services. In addition, in the same year, 3.4 million Fee-for-services (FFS) Medicare beneficiaries were provided care in 5,603 Medicare-certified ASCs.

A growing number of ASCs is expected to drive the overall market. As per MedPAC analysis, in the United States., the total number of ASCs increased to 5,603 in 2017 from 5,216 in 2012. In addition, the number of new ASCs increased to 189 in 2017 from 176 in 2012. ASCs previously used to perform a single specialty. However, the growing adoption of these settings for different applications is expected to boost the number of multispecialty ASCs. The number of multispecialty ASCs in the U.S. increased to 1,878 in 2017 from 1,802 in 2015. They can perform specialty treatments, such as pain management, orthopedics, and ophthalmology, which is expected to propel market growth.

Global Anti-Biofilm Wound Dressing Market Restraint

Rising Treatment Cost

In a hospital setting, around 25% to 40% of beds are occupied by wound patients. Wounds take longer to heal and require many resources for their treatment. The human cost of wounds is measured in terms of prolonged hospital stay, pain, chronic morbidity, and distress. For instance, a stage IV pressure ulcer causes considerable pain, adding around three months or longer to hospital stays, thereby increasing the patient burden. Similarly, wound infection can lead to inflammation and pain, increasing the need for surgical interventions or dressings such as anti-biofilms to reduce wound infections.

Wound costs in acute settings involve 15% to 20% of materials costs, 30% to 35% of nurse time, and more than 50% of hospitalization, making wound care expensive. In addition, wound dressing is required to be changed frequently, which adds to the treatment cost. The estimated cost of treating chronic wounds is around USD 3.48 to USD 4.32 million per annum, which accounts for 2% to 3% of the healthcare budget. Therefore, high treatment costs can result in lower adoption of anti-biofilm wound dressing, which, in turn, can hinder the overall market growth during the forecast period.

Global Anti-Biofilm Wound Dressing Market Opportunities

Increasing Number Of Accidents

The market is driven by the rise in accidents, including slips, trips, burns, and road accidents, as well as other ailments. Around 50 million individuals have been affected annually by vehicle accidents. These patients need medical help from different wound dressings that promote wound healing and are anti-biofilm. Similarly, according to Health and Safety Middle East (HSME), hundreds of people suffer injuries each year in workplaces due to trips, slips, and falls. Increased burn injury instances are also anticipated to fuel market expansion. According to the CDC, 1.1 million burn injuries in the U.S. require medical attention yearly. Around 50,000 of these people require hospitalization, increasing the need for anti-biofilm wound dressings.

Regional Analysis

By Region, the global anti-biofilm wound dressing market is segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa

North America accounted for the largest market share and is estimated to grow at a CAGR of 9.5%. Well-developed infrastructure, skilled staff, and increased healthcare expenditure contribute to this region's market growth. An increase in the incidence of chronic wounds, a rise in road accidents, and the presence of large ambulatory surgical centers are a few factors driving the market. For instance, as per the nonprofit National Safety Council, in 2020, around 42,060 people died in road accidents in the U.S., representing an 8% increase from 2019. Furthermore, according to CDC, road traffic accidents are among the key cause of death in the U.S. for people aged between 1 and 54. Hence, all such instances propel the market growth.

Europe is the second largest region. It is estimated to reach an expected value of USD 160 million by 2030 at a CAGR of 9.1%. Wounds are a growing concern in Europe, and their treatment involves many resources. Various surveys conducted in the U.K. have reported that the prevalence of wounds is 3-4 per 1,000 people. In addition, it is estimated that around 400,000 to 600,000 new diabetic foot ulcers will be diagnosed annually, and approximately one million new venous leg ulcers yearly. The demand for wound care in Europe is expected to grow due to the aging population and increase in long-term chronic conditions. Thereby driving the anti-biofilm wound dressing market in the region. The diagnosis and treatment of chronic wounds is a massive challenge in various disciplines of medicine, due to which the board of the German Wound Association, an initiative for Chronic Wounds (C.W.), has started defining multiple terms and procedures related to wounds, such as easy-to-remember algorithm ABCDE rule for treatment of chronic wounds. In addition, the 26th Conference of the European Wound Management Association (EWMA) was held in Germany. Thus, increasing government initiatives, growing awareness initiatives by various organizations, and a rising number of chronic wounds are expected to drive the market. For instance, per an article published in EWMA journal, in Germany, more than 4.5 million people are treated for chronic wounds yearly, costing around USD 5 billion.

The Asia Pacific is the third largest region. Developing countries, such as Japan and China, boost the market growth in the region. In addition, a large patient population, an increase in healthcare expenditure, and a rise in the number of road accidents are expected to drive the market in this region. According to various studies conducted in China, around 100 million patients require wound care every year, and about 30 million are skin wounds. The number of wound care centers in China has increased from 16 in 2010 to 357 in 2019. Furthermore, in December 2019, the National Health Commission of China released a notice for promoting the management of diagnosis and treatment of chronic skin wounds. This system includes setting up wound treatment departments and training specialized doctors & nurses. In China, more than 95% of the residents have social health insurance, which covers access to all primary healthcare institutions and public hospitals, including some private hospitals. Thus, the increasing prevalence of chronic wounds, government initiatives, and improvements in healthcare facilities are expected to drive the market in China.

Segmental Analysis

The global anti-biofilm wound dressing devices market is segmented by mode of mechanism, application and region. 

Based on The Mode of Mechanism, the global anti-biofilm wound dressing devices market has been segmented into physical, chemical, and biological. The physical segment is further into manual debridement, pulse electrical field, and ultrasound debridement. The chemical segment is further segregated into ionic silver, iodine, EDTA, and others. The biological segment is further segmented into lactoferrin, dispersion B, bacteriophage, and others. The chemical segment is expected to dominate the overall market and grow at the highest CAGR of 9.8% during the forecast period. The chemical mode of mechanism is expected to grow substantially over the forecast period, because of the increasing prevalence of chronic wounds and a growing number of surgeries across the globe. The chemical-based anti-biofilm wound dressing products allow multi-faceted action against biofilms, increasing the healing rate and recovery efficiency of chronic wounds. They can also help reduce the biofilm burden on chronic & acute wounds and lower the risk of acquiring recontamination with microorganisms. 

The physical segment is the second largest. The physical mode of mechanism is growing significantly, owing to increased efforts by researchers to boost R&D activities and innovations in anti-biofilm wound dressing products. For instance, in June 2020, the U.K.'s National Biofilms Innovation Centre announced a grant of USD 28,949.03 for research and introducing new product lines related to managing, engineering, and detecting biofilms. The physical mode of mechanism is further fragmented into manual debridement, pulse electrical field, and ultrasound debridement.

Based on Application, the global anti-biofilm wound dressing market is segmented into acute and chronic wounds. Acute wounds are further segmented into surgical & traumatic wounds and burn wounds. Chronic wounds are further segregated into diabetic foot ulcers, pressure ulcers, venous leg ulcers, and others. The acute wound segment dominated the market and is expected to grow by 9.3% during the forecast period. The surgical & traumatic wounds sub-segment held the largest share in 2020, owing to the increasing trauma cases across the globe. A traumatic wound is a sudden injury. They can range from minor ones, such as skinned knees, to severe injuries, such as gunshot wounds. Traumatic wounds include abrasions, lacerations, skin tears, bites, and penetrating trauma wounds. Anti-biofilm wound dressings are preferable for dressing such types of wounds. Treating traumatic wounds with these dressings involves repairing damage to the body's underlying tissue structures, removing any foreign particles, and allowing for the drainage of wounds. These steps can help prevent infections and promote healing, contributing to segment growth. In addition, the growing number of surgical site infections is another major factor driving the segment. Surgical wounds primarily occur due to surgical site infections. As per the Journal of Patient Safety & Infection Control in 2016, estimates for surgical site infections in India were significantly high, ranging from 23.0% to 38.0%, compared to global estimates, which vary from 0.5% to 15%. Hence, considerable segment growth is anticipated over the forecast period.

The chronic wound segment is the second largest. Chronic or non-healing wounds occur when there is no significant healing of an injury for about four weeks. These wounds progress and heal slower than expected or may not recover. The symptoms of chronic wounds include increased infection and pain at the site. This can be due to pressure on or around the wound, exposure to bacteria or trauma, or insufficient blood & oxygen supply. It is estimated that 1% to 2% of the population will suffer from a chronic wound at least once in their lifetime. As per the U.S. National Institutes of Health, in the U.S., chronic wounds affect around 6.5 million people in 2017, and the number will likely increase. A growing worldwide aging population is predicted to increase the prevalence of chronic wounds, placing a heavy financial load on the healthcare sector.

Recent Developments

• May 2022 - According to recent research, patients with long-term health disorders endure stigma and emotional difficulties connected to their health state. The results of the poll also show that their care teams, particularly the nurses, believe they don't have the time or resources to offer effective support. 200 American patients or their caregivers and 200 nurses participated in the poll, carried out by Wakefield Research with financial assistance from Convatec.

• May 2022 - Convatec Group Plc [CTEC: LON] announced that it has invested $30 million in BlueWind Medical, Ltd. ("BlueWind Medical") as part of BlueWind Medical's $64 million Series B funding round. Convatec led this round of financing. BlueWind Medical is the developer of RENOVA iStimTM, an implantable tibial neuromodulation device, presently in development, for the treatment of urge incontinence alone or in combination with urinary urgency and urinary frequency.